计算统计学方法评估乳腺癌风险分层的血液生物标志物。

IF 3 4区 医学 Q3 Biochemistry, Genetics and Molecular Biology Hormones & Cancer Pub Date : 2020-02-01 DOI:10.1007/s12672-019-00372-3
Kaan Oktay, Ashlie Santaliz-Casiano, Meera Patel, Natascia Marino, Anna Maria V Storniolo, Hamdi Torun, Burak Acar, Zeynep Madak Erdogan
{"title":"计算统计学方法评估乳腺癌风险分层的血液生物标志物。","authors":"Kaan Oktay,&nbsp;Ashlie Santaliz-Casiano,&nbsp;Meera Patel,&nbsp;Natascia Marino,&nbsp;Anna Maria V Storniolo,&nbsp;Hamdi Torun,&nbsp;Burak Acar,&nbsp;Zeynep Madak Erdogan","doi":"10.1007/s12672-019-00372-3","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is the second leading cause of cancer mortality among women. Mammography and tumor biopsy followed by histopathological analysis are the current methods to diagnose breast cancer. Mammography does not detect all breast tumor subtypes, especially those that arise in younger women or women with dense breast tissue, and are more aggressive. There is an urgent need to find circulating prognostic molecules and liquid biopsy methods for breast cancer diagnosis and reducing the mortality rate. In this study, we systematically evaluated metabolites and proteins in blood to develop a pipeline to identify potential circulating biomarkers for breast cancer risk. Our aim is to identify a group of molecules to be used in the design of portable and low-cost biomarker detection devices. We obtained plasma samples from women who are cancer free (healthy) and women who were cancer free at the time of blood collection but developed breast cancer later (susceptible). We extracted potential prognostic biomarkers for breast cancer risk from plasma metabolomics and proteomics data using statistical and discriminative power analyses. We pre-processed the data to ensure the quality of subsequent analyses, and used two main feature selection methods to determine the importance of each molecule. After further feature elimination based on pairwise dependencies, we measured the performance of logistic regression classifier on the remaining molecules and compared their biological relevance. We identified six signatures that predicted breast cancer risk with different specificity and selectivity. The best performing signature had 13 factors. We validated the difference in level of one of the biomarkers, SCF/KITLG, in plasma from healthy and susceptible individuals. These biomarkers will be used to develop low-cost liquid biopsy methods toward early identification of breast cancer risk and hence decreased mortality. Our findings provide the knowledge basis needed to proceed in this direction.</p>","PeriodicalId":13060,"journal":{"name":"Hormones & Cancer","volume":"11 1","pages":"17-33"},"PeriodicalIF":3.0000,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12672-019-00372-3","citationCount":"20","resultStr":"{\"title\":\"A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification.\",\"authors\":\"Kaan Oktay,&nbsp;Ashlie Santaliz-Casiano,&nbsp;Meera Patel,&nbsp;Natascia Marino,&nbsp;Anna Maria V Storniolo,&nbsp;Hamdi Torun,&nbsp;Burak Acar,&nbsp;Zeynep Madak Erdogan\",\"doi\":\"10.1007/s12672-019-00372-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Breast cancer is the second leading cause of cancer mortality among women. Mammography and tumor biopsy followed by histopathological analysis are the current methods to diagnose breast cancer. Mammography does not detect all breast tumor subtypes, especially those that arise in younger women or women with dense breast tissue, and are more aggressive. There is an urgent need to find circulating prognostic molecules and liquid biopsy methods for breast cancer diagnosis and reducing the mortality rate. In this study, we systematically evaluated metabolites and proteins in blood to develop a pipeline to identify potential circulating biomarkers for breast cancer risk. Our aim is to identify a group of molecules to be used in the design of portable and low-cost biomarker detection devices. We obtained plasma samples from women who are cancer free (healthy) and women who were cancer free at the time of blood collection but developed breast cancer later (susceptible). We extracted potential prognostic biomarkers for breast cancer risk from plasma metabolomics and proteomics data using statistical and discriminative power analyses. We pre-processed the data to ensure the quality of subsequent analyses, and used two main feature selection methods to determine the importance of each molecule. After further feature elimination based on pairwise dependencies, we measured the performance of logistic regression classifier on the remaining molecules and compared their biological relevance. We identified six signatures that predicted breast cancer risk with different specificity and selectivity. The best performing signature had 13 factors. We validated the difference in level of one of the biomarkers, SCF/KITLG, in plasma from healthy and susceptible individuals. These biomarkers will be used to develop low-cost liquid biopsy methods toward early identification of breast cancer risk and hence decreased mortality. Our findings provide the knowledge basis needed to proceed in this direction.</p>\",\"PeriodicalId\":13060,\"journal\":{\"name\":\"Hormones & Cancer\",\"volume\":\"11 1\",\"pages\":\"17-33\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2020-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s12672-019-00372-3\",\"citationCount\":\"20\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hormones & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12672-019-00372-3\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormones & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-019-00372-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 20

摘要

乳腺癌是妇女癌症死亡的第二大原因。乳房x光检查和肿瘤活检后进行组织病理学分析是目前诊断乳腺癌的方法。乳房x光检查不能检测到所有的乳腺肿瘤亚型,特别是那些出现在年轻女性或乳腺组织致密的女性中,并且更具侵袭性的肿瘤。迫切需要寻找循环预后分子和液体活检方法来诊断乳腺癌并降低死亡率。在这项研究中,我们系统地评估了血液中的代谢物和蛋白质,以建立一个管道来识别乳腺癌风险的潜在循环生物标志物。我们的目标是确定一组分子,用于设计便携式和低成本的生物标志物检测设备。我们从没有癌症(健康)的妇女和在采血时没有癌症但后来患乳腺癌(易感)的妇女中获得血浆样本。我们使用统计和判别能力分析从血浆代谢组学和蛋白质组学数据中提取乳腺癌风险的潜在预后生物标志物。我们对数据进行了预处理,以确保后续分析的质量,并使用两种主要的特征选择方法来确定每个分子的重要性。在基于两两依赖关系的进一步特征消除之后,我们测量了逻辑回归分类器在剩余分子上的性能,并比较了它们的生物学相关性。我们确定了六个特征,以不同的特异性和选择性预测乳腺癌的风险。表现最好的签名有13个因素。我们验证了健康和易感个体血浆中其中一种生物标志物SCF/KITLG水平的差异。这些生物标志物将用于开发低成本的液体活检方法,以早期识别乳腺癌风险,从而降低死亡率。我们的研究结果为朝这个方向前进提供了必要的知识基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification.

Breast cancer is the second leading cause of cancer mortality among women. Mammography and tumor biopsy followed by histopathological analysis are the current methods to diagnose breast cancer. Mammography does not detect all breast tumor subtypes, especially those that arise in younger women or women with dense breast tissue, and are more aggressive. There is an urgent need to find circulating prognostic molecules and liquid biopsy methods for breast cancer diagnosis and reducing the mortality rate. In this study, we systematically evaluated metabolites and proteins in blood to develop a pipeline to identify potential circulating biomarkers for breast cancer risk. Our aim is to identify a group of molecules to be used in the design of portable and low-cost biomarker detection devices. We obtained plasma samples from women who are cancer free (healthy) and women who were cancer free at the time of blood collection but developed breast cancer later (susceptible). We extracted potential prognostic biomarkers for breast cancer risk from plasma metabolomics and proteomics data using statistical and discriminative power analyses. We pre-processed the data to ensure the quality of subsequent analyses, and used two main feature selection methods to determine the importance of each molecule. After further feature elimination based on pairwise dependencies, we measured the performance of logistic regression classifier on the remaining molecules and compared their biological relevance. We identified six signatures that predicted breast cancer risk with different specificity and selectivity. The best performing signature had 13 factors. We validated the difference in level of one of the biomarkers, SCF/KITLG, in plasma from healthy and susceptible individuals. These biomarkers will be used to develop low-cost liquid biopsy methods toward early identification of breast cancer risk and hence decreased mortality. Our findings provide the knowledge basis needed to proceed in this direction.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hormones & Cancer
Hormones & Cancer ONCOLOGY-ENDOCRINOLOGY & METABOLISM
CiteScore
4.60
自引率
0.00%
发文量
0
期刊介绍: Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science, pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research. In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies.
期刊最新文献
Welcome from the new Discover Oncology journal : Editorial - 28th December, 2020. Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis. Prevalence of Histological Characteristics of Breast Cancer in Rwanda in Relation to Age and Tumor Stages. The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication. Outcome of Clinical Genetic Testing in Patients with Features Suggestive for Hereditary Predisposition to PTH-Mediated Hypercalcemia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1